MBB Public Markets I LLC Purchases 11,488 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

MBB Public Markets I LLC raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 440.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,095 shares of the medical equipment provider’s stock after acquiring an additional 11,488 shares during the quarter. MBB Public Markets I LLC’s holdings in Zimmer Biomet were worth $1,530,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently bought and sold shares of ZBH. D. E. Shaw & Co. Inc. lifted its position in shares of Zimmer Biomet by 329.2% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 490,138 shares of the medical equipment provider’s stock valued at $53,195,000 after buying an additional 375,929 shares in the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Zimmer Biomet by 75.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 6,997 shares of the medical equipment provider’s stock valued at $759,000 after acquiring an additional 3,005 shares during the last quarter. APG Asset Management N.V. lifted its position in shares of Zimmer Biomet by 12.6% in the second quarter. APG Asset Management N.V. now owns 176,729 shares of the medical equipment provider’s stock worth $17,896,000 after buying an additional 19,811 shares in the last quarter. APG Asset Management US Inc. raised its holdings in shares of Zimmer Biomet by 1.4% during the 2nd quarter. APG Asset Management US Inc. now owns 176,631 shares of the medical equipment provider’s stock worth $18,716,000 after acquiring an additional 2,436 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in Zimmer Biomet by 1.8% during the second quarter. AQR Capital Management LLC now owns 420,779 shares of the medical equipment provider’s stock valued at $45,360,000 after purchasing an additional 7,358 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several recent research reports. Robert W. Baird decreased their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Canaccord Genuity Group lowered their price objective on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 10th. Oppenheimer dropped their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Truist Financial restated a “hold” rating and issued a $112.00 price target (down from $117.00) on shares of Zimmer Biomet in a report on Friday, September 13th. Finally, TD Cowen lowered their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research report on Friday, September 6th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $125.17.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $108.22 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63. The stock has a market capitalization of $22.04 billion, a price-to-earnings ratio of 23.42, a PEG ratio of 1.98 and a beta of 1.02. The firm’s 50 day simple moving average is $109.65 and its 200-day simple moving average is $114.69. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the firm posted $1.82 earnings per share. The company’s revenue was up 3.9% compared to the same quarter last year. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.